An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

The actress and comedian talks about her experience with Zepbound, and how it's contributed to her bigger health goals ...

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 4.1% in the morning session after the company ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

Roughly 16 million American adults are taking GLP-1 medications. They are a major breakthrough for people to shed pounds and ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

More than half of large employers plan to scale back health care benefits next year as rising costs from weight-loss and specialty drugs squeeze budgets, according to a new survey released by ...

LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...